RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06313086, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. 3.Patients with unresectable locally advanced or metastatic breast cancer confirmed by histology;

    Inclusion criterion 3

  3. 5.Previously received regimens containing trastuzumab and taxanes at the advanced stage of disease.

    Inclusion criterion 5

  4. 1. Patients who have previously received tubulin inhibitor-loaded HER2 ADC therapy

    Exclusion criterion 1

    5. Has not recovered from adverse reactions caused by previous anti-tumor treatments to ≤ Grade 1 or baseline (refer to NCI CTCAE 5.0);

    Exclusion criterion 5

    6. NCI-CTCAE 5.0 ≥Grade 2 peripheral nephropathy occurred during previous systemic anti-tumor treatment;

    Exclusion criterion 6

    7. Received immunotherapy, macromolecular targeted therapy or other anti-tumor biological therapy within 4 weeks before randomization, or received endocrine therapy, cytotoxic drug chemotherapy and small molecular targeted drug therapy within 2 weeks before randomization, or received traditional Chinese medicine preparations with anti-tumor indications within 2 weeks before randomization .

    Exclusion criterion 7

  5. 6.The Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2;

    Inclusion criterion 6

  6. 2. History of any other malignant tumors within three years

    Exclusion criterion 2

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06313086, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • 1.Voluntarily agree to participate in the study and sign the informed consent;
  • 2.Age≥18 years old;
  • 3.Patients with unresectable locally advanced or metastatic breast cancer confirmed by histology;
  • 4.Confirmed to be HER2 positive (HER2-positive is defined as IHC 3+ or IHC 2+ with ISH positive);
  • 5.Previously received regimens containing trastuzumab and taxanes at the advanced stage of disease.
  • 6.The Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2;
  • 7.Patients with adequate organ functions;
  • 8.Life expectancy ≥ 3 months;
  • 9.Female and male patients of childbearing age must agree to take adequate contraceptive measures during the entire study period.

Exclusion Criteria:

  • 1. Patients who have previously received tubulin inhibitor-loaded HER2 ADC therapy
  • 2. History of any other malignant tumors within three years
  • 3. With uncontrollable serous effusion within 14 days before randomization, which required frequent drainage or medical intervention.
  • 4. Known contraindication to the study drugs;
  • 5. Has not recovered from adverse reactions caused by previous anti-tumor treatments to ≤ Grade 1 or baseline (refer to NCI CTCAE 5.0);
  • 6. NCI-CTCAE 5.0 ≥Grade 2 peripheral nephropathy occurred during previous systemic anti-tumor treatment;
  • 7. Received immunotherapy, macromolecular targeted therapy or other anti-tumor biological therapy within 4 weeks before randomization, or received endocrine therapy, cytotoxic drug chemotherapy and small molecular targeted drug therapy within 2 weeks before randomization, or received traditional Chinese medicine preparations with anti-tumor indications within 2 weeks before randomization .
  • 8. Major organ surgery (excluding needle biopsy) within 28 days before randomization;
  • 9. Untreated (including baseline findings) or unstable cerebral parenchymal metastasis, spinal cord metastasis or compression, and cancerous meningitis.
  • 10.The cumulative amount of previous exposure to anthracyclines has reached the dosage;
  • 11.History of LVEF < 40%, symptomatic congestive heart failure (CHF),
  • 12.Serious or uncontrolled cardiovascular disease;
  • 13.History of (non-infectious) interstitial lung disease/pneumonitis requiring steroid hormone therapy;
  • 14.Patients who currently have ocular diseases that require medication or surgical intervention; or unwilling to stop wearing contact lenses during the study.
  • 15.Active infections requiring intravenous antibiotics, antivirals, or antifungals within 14 days before randomization;
  • 16.There are other circumstances that may interfere with the subject's participation in the study procedures or do not meet the subject's maximum benefit from participating in the study or affect the study results.

Quoted from ClinicalTrials.gov, NCT06313086, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06313086, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06313086